0 32

Cited 3 times in

Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease

DC FieldValueLanguage
dc.contributor.author신성재-
dc.date.accessioned2018-07-20T08:20:26Z-
dc.date.available2018-07-20T08:20:26Z-
dc.date.issued2017-
dc.identifier.issn1027-3719-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161104-
dc.description.abstractSETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE: To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS: With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONCLUSION: Our results suggest that once-daily AMK for 4 weeks with a target Cmax of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherThe Union-
dc.relation.isPartOfInternational Journal of Tuberculosis and Lung Disease-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAmikacin/administration & dosage*-
dc.subject.MESHAmikacin/adverse effects-
dc.subject.MESHAmikacin/pharmacokinetics-
dc.subject.MESHAnti-Bacterial Agents/administration & dosage*-
dc.subject.MESHAnti-Bacterial Agents/adverse effects-
dc.subject.MESHAnti-Bacterial Agents/pharmacokinetics-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHDrug Monitoring/methods-
dc.subject.MESHFemale-
dc.subject.MESHHearing Loss/chemically induced-
dc.subject.MESHHearing Loss/epidemiology-
dc.subject.MESHHumans-
dc.subject.MESHKidney Diseases/chemically induced-
dc.subject.MESHKidney Diseases/epidemiology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHMycobacterium Infections, Nontuberculous/drug therapy*-
dc.subject.MESHMycobacterium Infections, Nontuberculous/microbiology-
dc.subject.MESHMycobacterium abscessus/isolation & purification*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTinnitus/chemically induced-
dc.subject.MESHTinnitus/epidemiology-
dc.titleOnce-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Microbiology-
dc.contributor.googleauthorLee, H.-
dc.contributor.googleauthorSohn, Y. M.-
dc.contributor.googleauthorKo, J. Y.-
dc.contributor.googleauthorLee, S-Y.-
dc.contributor.googleauthorJhun, B. W.-
dc.contributor.googleauthorPark, H. Y.-
dc.contributor.googleauthorJeon, K.-
dc.contributor.googleauthorKim, D. H.-
dc.contributor.googleauthorKim, S-Y.-
dc.contributor.googleauthorChoi, J. E.-
dc.contributor.googleauthorMoon, I. J.-
dc.contributor.googleauthorShin, S. J.-
dc.contributor.googleauthorPark, H. J.-
dc.contributor.googleauthorKoh, W-J.-
dc.identifier.doi10.5588/ijtld.16.0791-
dc.contributor.localIdA02114-
dc.relation.journalcodeJ01167-
dc.identifier.eissn1815-7920-
dc.identifier.pmid28633708-
dc.identifier.urlhttp://www.ingentaconnect.com/contentone/iuatld/ijtld/2017/00000021/00000007/art00018-
dc.contributor.alternativeNameShin, Sung Jae-
dc.contributor.affiliatedAuthorShin, Sung Jae-
dc.citation.volume21-
dc.citation.number7-
dc.citation.startPage818-
dc.citation.endPage824-
dc.identifier.bibliographicCitationInternational Journal of Tuberculosis and Lung Disease, Vol.21(7) : 818-824, 2017-
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실)

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.